1887

Abstract

Epstein–Barr virus (EBV) latently infected B-cells are the precursors of EBV-associated malignancies. EBV-infection induces the production of pro-survival and anti-inflammatory cytokines that may be important in the transition between latency and malignancy. One EBV protein, LMP2A, can be detected in both latently infected resting B-cells and in EBV-associated malignancies. Therefore, we tested the ability of LMP2A to influence cytokine production using both LMP2A-Tg primary B-cells and LMP2A-expressing B-cell lines. Our data demonstrate that LMP2A does not globally alter B-cell-produced cytokine levels, but specifically targets IL-10. Additional studies using ELISA and real-time-RT-PCR confirm that LMP2A utilizes PI3-kinase to increase IL-10 levels. Finally, the data demonstrate that LMP2A-expressing B-cell lines are more dependent on IL-10 for survival in comparison to LMP2A-negative B-cell lines. These data identify a novel function of LMP2A in the alteration of a cytokine that is important for both tumour survival and anti-tumour responses.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.049221-0
2013-05-01
2019-12-08
Loading full text...

Full text loading...

/deliver/fulltext/jgv/94/5/1127.html?itemId=/content/journal/jgv/10.1099/vir.0.049221-0&mimeType=html&fmt=ahah

References

  1. Babcock G. J. , Decker L. L. , Volk M. , Thorley-Lawson D. A. . ( 1998; ). EBV persistence in memory B cells in vivo. . Immunity 9:, 395–404. [CrossRef] [PubMed]
    [Google Scholar]
  2. Babcock G. J. , Hochberg D. , Thorley-Lawson A. D. . ( 2000; ). The expression pattern of Epstein–Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. . Immunity 13:, 497–506. [CrossRef] [PubMed]
    [Google Scholar]
  3. Babcock G. J. , Miyashita-Lin E. M. , Thorley-Lawson D. A. . ( 2001; ). Detection of EBV infection at the single-cell level. Precise quantitation of virus-infected cells in vivo. . Methods Mol Biol 174:, 103–110.[PubMed]
    [Google Scholar]
  4. Banchereau J. , Blanchard D. , Brière F. , Galizzi J. P. , Garrone P. , Hermann P. , Lebecque S. , Rousset F. . ( 1993; ). Role of cytokines in human B lymphocyte growth and differentiation. . Nouv Rev Fr Hematol 35:, 61–66.[PubMed]
    [Google Scholar]
  5. Beatty P. R. , Krams S. M. , Martinez O. M. . ( 1997; ). Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. . J Immunol 158:, 4045–4051.[PubMed]
    [Google Scholar]
  6. Bechtel D. , Kurth J. , Unkel C. , Küppers R. . ( 2005; ). Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. . Blood 106:, 4345–4350. [CrossRef] [PubMed]
    [Google Scholar]
  7. Bell A. I. , Groves K. , Kelly G. L. , Croom-Carter D. , Hui E. , Chan A. T. , Rickinson A. B. . ( 2006; ). Analysis of Epstein–Barr virus latent gene expression in endemic Burkitt’s lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. . J Gen Virol 87:, 2885–2890. [CrossRef] [PubMed]
    [Google Scholar]
  8. Brennan P. . ( 2001; ). Signalling events regulating lymphoid growth and survival. . Semin Cancer Biol 11:, 415–421. [CrossRef] [PubMed]
    [Google Scholar]
  9. Bultema R. , Longnecker R. , Swanson-Mungerson M. . ( 2009; ). Epstein–Barr virus LMP2A accelerates MYC-induced lymphomagenesis. . Oncogene 28:, 1471–1476. [CrossRef] [PubMed]
    [Google Scholar]
  10. Burdin N. , Van Kooten C. , Galibert L. , Abrams J. S. , Wijdenes J. , Banchereau J. , Rousset F. . ( 1995; ). Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. . J Immunol 154:, 2533–2544.[PubMed]
    [Google Scholar]
  11. Caldwell R. G. , Wilson J. B. , Anderson S. J. , Longnecker R. . ( 1998; ). Epstein–Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. . Immunity 9:, 405–411. [CrossRef] [PubMed]
    [Google Scholar]
  12. Cortes J. , Kurzrock R. . ( 1997; ). Interleukin-10 in non-Hodgkin’s lymphoma. . Leuk Lymphoma 26:, 251–259.[PubMed]
    [Google Scholar]
  13. de Waal Malefyt R. , Abrams J. , Bennett B. , Figdor C. G. , de Vries J. E. . ( 1991; ). Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. . J Exp Med 174:, 1209–1220. [CrossRef] [PubMed]
    [Google Scholar]
  14. Decker L. L. , Klaman L. D. , Thorley-Lawson D. A. . ( 1996; ). Detection of the latent form of Epstein–Barr virus DNA in the peripheral blood of healthy individuals. . J Virol 70:, 3286–3289.[PubMed]
    [Google Scholar]
  15. Enk A. H. , Katz S. I. . ( 1992; ). Identification and induction of keratinocyte-derived IL-10. . J Immunol 149:, 92–95.[PubMed]
    [Google Scholar]
  16. Fukuda M. , Longnecker R. . ( 2004; ). Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. . J Virol 78:, 1697–1705. [CrossRef] [PubMed]
    [Google Scholar]
  17. Hatton O. , Phillips L. K. , Vaysberg M. , Hurwich J. , Krams S. M. , Martinez O. M. . ( 2011; ). Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein–Barr virus+ (EBV+) B cell lymphomas. . J Biol Chem 286:, 37368–37378. [CrossRef] [PubMed]
    [Google Scholar]
  18. Hochberg D. , Middeldorp J. M. , Catalina M. , Sullivan J. L. , Luzuriaga K. , Thorley-Lawson D. A. . ( 2004; ). Demonstration of the Burkitt’s lymphoma Epstein–Barr virus phenotype in dividing latently infected memory cells in vivo. . Proc Natl Acad Sci U S A 101:, 239–244. [CrossRef] [PubMed]
    [Google Scholar]
  19. Ikeda M. , Longnecker R. . ( 2007; ). Cholesterol is critical for Epstein–Barr virus latent membrane protein 2A trafficking and protein stability. . Virology 360:, 461–468. [CrossRef] [PubMed]
    [Google Scholar]
  20. Ikeda A. , Merchant M. , Lev L. , Longnecker R. , Ikeda M. . ( 2004; ). Latent membrane protein 2A, a viral B cell receptor homologue, induces CD5+ B-1 cell development. . J Immunol 172:, 5329–5337.[PubMed] [CrossRef]
    [Google Scholar]
  21. Jochum S. , Moosmann A. , Lang S. , Hammerschmidt W. , Zeidler R. . ( 2012; ). The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. . PLoS Pathog 8:, e1002704. [CrossRef] [PubMed]
    [Google Scholar]
  22. Khatri V. P. , Caligiuri M. A. . ( 1998; ). A review of the association between interleukin-10 and human B-cell malignancies. . Cancer Immunol Immunother 46:, 239–244. [CrossRef] [PubMed]
    [Google Scholar]
  23. Konforte D. , Paige C. J. . ( 2009; ). Interleukin-21 regulates expression of the immediate-early lytic cycle genes and proteins in Epstein–Barr virus infected B cells. . Virus Res 144:, 339–343. [CrossRef] [PubMed]
    [Google Scholar]
  24. Lambert S. L. , Martinez O. M. . ( 2007; ). Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. . J Immunol 179:, 8225–8234.[PubMed] [CrossRef]
    [Google Scholar]
  25. Liu Y. , de Waal Malefyt R. , Briere F. , Parham C. , Bridon J. M. , Banchereau J. , Moore K. W. , Xu J. . ( 1997; ). The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. . J Immunol 158:, 604–613.[PubMed]
    [Google Scholar]
  26. Longnecker R. , Miller C. L. , Miao X. Q. , Marchini A. , Kieff E. . ( 1992; ). The only domain which distinguishes Epstein–Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential. . J Virol 66:, 6461–6469.[PubMed]
    [Google Scholar]
  27. Mancao C. , Hammerschmidt W. . ( 2007; ). Epstein–Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. . Blood 110:, 3715–3721. [CrossRef] [PubMed]
    [Google Scholar]
  28. Miller C. L. , Longnecker R. , Kieff E. . ( 1993; ). Epstein–Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. . J Virol 67:, 3087–3094.[PubMed]
    [Google Scholar]
  29. Mizoguchi A. , Bhan A. K. . ( 2006; ). A case for regulatory B cells. . J Immunol 176:, 705–710.[PubMed] [CrossRef]
    [Google Scholar]
  30. Niedobitek G. , Agathanggelou A. , Herbst H. , Whitehead L. , Wright D. H. , Young L. S. . ( 1997; ). Epstein–Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. . J Pathol 182:, 151–159. [CrossRef] [PubMed]
    [Google Scholar]
  31. O’Garra A. , Howard M. . ( 1992; ). Cytokines and Ly-1 (B1) B cells. . Int Rev Immunol 8:, 219–234. [CrossRef] [PubMed]
    [Google Scholar]
  32. O’Garra A. , Vieira P. . ( 2007; ). T(H)1 cells control themselves by producing interleukin-10. . Nat Rev Immunol 7:, 425–428. [CrossRef] [PubMed]
    [Google Scholar]
  33. O’Garra A. , Stapleton G. , Dhar V. , Pearce M. , Schumacher J. , Rugo H. , Barbis D. , Stall A. , Cupp J. . & other authors ( 1990; ). Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. . Int Immunol 2:, 821–832. [CrossRef] [PubMed]
    [Google Scholar]
  34. Portis T. , Longnecker R. . ( 2004; ). Epstein–Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. . Oncogene 23:, 8619–8628. [CrossRef] [PubMed]
    [Google Scholar]
  35. Rochford R. , Miller C. L. , Cannon M. J. , Izumi K. M. , Kieff E. , Longnecker R. . ( 1997; ). In vivo growth of Epstein–Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2). . Arch Virol 142:, 707–720. [CrossRef] [PubMed]
    [Google Scholar]
  36. Rode H. J. , Bugert J. J. , Handermann M. , Schnitzler P. , Kehm R. , Janssen W. , Delius H. , Darai G. . ( 1994; ). Molecular characterization and determination of the coding capacity of the genome of equine herpesvirus type 2 between the genome coordinates 0.235 and 0.258 (the EcoRI DNA fragment N; 4.2 kbp). . Virus Genes 9:, 61–75. [CrossRef] [PubMed]
    [Google Scholar]
  37. Samanta M. , Iwakiri D. , Takada K. . ( 2008; ). Epstein–Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. . Oncogene 27:, 4150–4160. [CrossRef] [PubMed]
    [Google Scholar]
  38. Saraiva M. , O’Garra A. . ( 2010; ). The regulation of IL-10 production by immune cells. . Nat Rev Immunol 10:, 170–181. [CrossRef] [PubMed]
    [Google Scholar]
  39. Swanson-Mungerson M. , Bultema R. , Longnecker R. . ( 2006; ). Epstein–Barr virus LMP2A enhances B-cell responses in vivo and in vitro. . J Virol 80:, 6764–6770. [CrossRef] [PubMed]
    [Google Scholar]
  40. Swanson-Mungerson M. , Bultema R. , Longnecker R. . ( 2010; ). Epstein–Barr virus LMP2A imposes sensitivity to apoptosis. . J Gen Virol 91:, 2197–2202. [CrossRef] [PubMed]
    [Google Scholar]
  41. Tsai S. C. , Lin S. J. , Chen P. W. , Luo W. Y. , Yeh T. H. , Wang H. W. , Chen C. J. , Tsai C. H. . ( 2009; ). EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. . Blood 114:, 109–118. [CrossRef] [PubMed]
    [Google Scholar]
  42. Vockerodt M. , Haier B. , Buttgereit P. , Tesch H. , Kube D. . ( 2001; ). The Epstein–Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt’s lymphoma cells but not in Hodgkin’s cells involving the p38/SAPK2 pathway. . Virology 280:, 183–198. [CrossRef] [PubMed]
    [Google Scholar]
  43. Yoon S. I. , Jones B. C. , Logsdon N. J. , Harris B. D. , Kuruganti S. , Walter M. R. . ( 2012; ). Epstein–Barr virus IL-10 engages IL-10R1 by a two-step mechanism leading to altered signaling properties. . J Biol Chem 287:, 26586–26595. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.049221-0
Loading
/content/journal/jgv/10.1099/vir.0.049221-0
Loading

Data & Media loading...

Supplements

Supplementary table 

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error